These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 34380291)

  • 1. Severe Lymphocytosis in a Case of Diffuse Large B-Cell Lymphoma Treated by Ibrutinib.
    Paydaş S; Bayram E; Türker M; Özer T
    Turk J Haematol; 2021 Dec; 38(4):337-338. PubMed ID: 34380291
    [No Abstract]   [Full Text] [Related]  

  • 2. Ibrutinib combined with venetoclax for the treatment of relapsed/refractory diffuse large B cell lymphoma.
    Zhou Z; Zhang L; Wang X; Li X; Li L; Fu X; Zhang X; Li Z; Sun Z; Zhang M
    Ann Hematol; 2021 Jun; 100(6):1509-1516. PubMed ID: 33900450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ibrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B-cell Lymphoma.
    Graf SA; Cassaday RD; Morris K; Voutsinas JM; Wu QV; Behnia S; Lynch RC; Krakow E; Rasmussen H; Chauncey TR; Kanan S; Soma L; Smith SD; Gopal AK
    Clin Lymphoma Myeloma Leuk; 2021 Mar; 21(3):176-181. PubMed ID: 33358575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An oral drug for chronic lymphocytic leukemia.
    Koehler A
    JAAPA; 2020 Feb; 33(2):51-53. PubMed ID: 31990837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ibrutinib skin toxicities: Report of two cases.
    Bloomquist MS; Curry JL; Krishnan B; Rivero G; Curry CV; Diwan AH
    J Cutan Pathol; 2022 Apr; 49(4):363-368. PubMed ID: 34726785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax.
    Gángó A; Kiss R; Farkas P; Hanna E; Demeter J; Deák B; Lévai D; Kotmayer L; Alpár D; Matolcsy A; Bödör C; Mátrai Z; Timár B
    Pathology; 2022 Feb; 54(1):95-103. PubMed ID: 34332791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification BCL6 and miR-30 family associating with Ibrutinib resistance in activated B-cell-like diffuse large B-cell lymphoma.
    Li J; Huang Y; Zhang Y; Wen J; Chen Y; Wang L; Jiang P; Hu J
    Med Oncol; 2021 Feb; 38(4):33. PubMed ID: 33629212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ibrutinib in primary central nervous system diffuse large B-cell lymphoma.
    T Low J; B Peters K
    CNS Oncol; 2020 Mar; 9(1):CNS51. PubMed ID: 32141313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PDGFD induces ibrutinib resistance of diffuse large B‑cell lymphoma through activation of EGFR.
    Jin J; Wang L; Tao Z; Zhang J; Lv F; Cao J; Hu X
    Mol Med Rep; 2020 May; 21(5):2209-2219. PubMed ID: 32186759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clonal-related transformation from Waldenström macroglobulinemia to diffuse large B cell lymphoma during the treatment of ibrutinib: a case report and literature review].
    Xia Y; Zhu HY; Wang L; Chen RZ; Chen W; Ding CY; Xu W; Li JY
    Zhonghua Xue Ye Xue Za Zhi; 2020 Sep; 41(9):770-772. PubMed ID: 33113611
    [No Abstract]   [Full Text] [Related]  

  • 11. Rituximab, lenalidomide, and ibrutinib in relapsed/refractory primary cutaneous diffuse large B-cell lymphoma, leg type.
    Moore DC; Soni AC; Hu B; Smith ET; Levine J; Moyo TK; Jacobs R; Ghosh N; Park SI
    Br J Haematol; 2022 Feb; 196(4):e30-e33. PubMed ID: 34642938
    [No Abstract]   [Full Text] [Related]  

  • 12. Activity of ibrutinib plus R-CHOP in diffuse large B-cell lymphoma: Response, pharmacodynamic, and biomarker analyses of a phase Ib study.
    Schaffer M; Chaturvedi S; Davis C; de Jong J; Aquino R; Oki Y; Fourneau N; Younes A; Balasubramanian S
    Cancer Treat Res Commun; 2020; 25():100235. PubMed ID: 33188997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Combination of ibrutinib and temozolomide for the treatment of newly diagnosed elderly primary central nervous system diffuse large B cell lymphoma: a case report].
    Wang L; Li X; He YZ
    Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):482. PubMed ID: 32654461
    [No Abstract]   [Full Text] [Related]  

  • 14. Chidamide combined with ibrutinib improved the prognosis of primary bone marrow diffuse large B cell lymphoma.
    Tian C; Chen Z; Li Y
    J Int Med Res; 2020 Jul; 48(7):300060520936053. PubMed ID: 32643971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pseudo-Richter transformation of chronic lymphocytic leukaemia/small lymphocytic lymphoma following ibrutinib interruption: a diagnostic pitfall.
    Barnea Slonim L; Ma S; Behdad A; Chen Q
    Br J Haematol; 2020 Oct; 191(1):e22-e25. PubMed ID: 32677079
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy of ibrutinib as salvage treatment in a secondary central nervous system lymphoma (SCNSL) progressed after chemorefractory Primary Mediastinal B Cell Lymphoma (PMBCL).
    Malfona F; Testi AM; Moleti ML; Petrucci L; Leccisotti L; Martelli M; Di Rocco A
    Leuk Lymphoma; 2022 Feb; 63(2):483-486. PubMed ID: 34612154
    [No Abstract]   [Full Text] [Related]  

  • 17. Hepatitis B Virus-associated Liver Failure in a Patient With B-cell Non-Hodgkin Lymphoma After Anti-cancer Therapy Including Ibrutinib.
    Malek AE; Nieto Y; Szvalb AD; Siddiqui S; Shafi MA; Hwang JP; Raad II; Torres HA
    Clin Lymphoma Myeloma Leuk; 2020 Mar; 20(3):e124-e127. PubMed ID: 31932250
    [No Abstract]   [Full Text] [Related]  

  • 18. Rapid Resolution of Presumed Vitreoretinal Lymphoma With Systemic Ibrutinib Therapy.
    Mathai M; Fein JG
    Ophthalmic Surg Lasers Imaging Retina; 2021 Apr; 52(4):227-230. PubMed ID: 34039188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BTK and PI3K Inhibitors Reveal Synergistic Inhibitory Anti-Tumoral Effects in Canine Diffuse Large B-Cell Lymphoma Cells.
    Kong W; Sender S; Taher L; Villa-Perez S; Ma Y; Sekora A; Ruetgen BC; Brenig B; Beck J; Schuetz E; Junghanss C; Nolte I; Murua Escobar H
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with temozolomide and ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL).
    Renaud L; Bossard JB; Carpentier B; Terriou L; Cambier N; Chanteau G; Escure G; Tilmont R; Barbieux S; Wemeau M; Hieulle J; Boyle EM; Morschhauser F
    Eur J Haematol; 2021 Sep; 107(3):370-373. PubMed ID: 34018260
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.